CN111909130B - 作为突变型异柠檬酸脱氢酶抑制剂的吡啶-2(1h)-酮喹啉酮衍生物 - Google Patents

作为突变型异柠檬酸脱氢酶抑制剂的吡啶-2(1h)-酮喹啉酮衍生物 Download PDF

Info

Publication number
CN111909130B
CN111909130B CN202010391529.6A CN202010391529A CN111909130B CN 111909130 B CN111909130 B CN 111909130B CN 202010391529 A CN202010391529 A CN 202010391529A CN 111909130 B CN111909130 B CN 111909130B
Authority
CN
China
Prior art keywords
oxo
methyl
chloro
amino
dihydroquinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010391529.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN111909130A (zh
Inventor
S.阿什韦尔
A-M.坎贝尔
J.A.卡拉韦拉
R.B.迪博尔德
A.埃里克森
G.古斯塔夫森
D.R.兰西雅
J.林
W.卢
Z.王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forma Therapeutics Inc
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Priority to CN202010391529.6A priority Critical patent/CN111909130B/zh
Publication of CN111909130A publication Critical patent/CN111909130A/zh
Application granted granted Critical
Publication of CN111909130B publication Critical patent/CN111909130B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CN202010391529.6A 2014-09-19 2015-09-18 作为突变型异柠檬酸脱氢酶抑制剂的吡啶-2(1h)-酮喹啉酮衍生物 Active CN111909130B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010391529.6A CN111909130B (zh) 2014-09-19 2015-09-18 作为突变型异柠檬酸脱氢酶抑制剂的吡啶-2(1h)-酮喹啉酮衍生物

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462053006P 2014-09-19 2014-09-19
US62/053,006 2014-09-19
US201562128089P 2015-03-04 2015-03-04
US62/128,089 2015-03-04
US201562150812P 2015-04-21 2015-04-21
US62/150,812 2015-04-21
PCT/US2015/051055 WO2016044789A1 (en) 2014-09-19 2015-09-18 Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
CN202010391529.6A CN111909130B (zh) 2014-09-19 2015-09-18 作为突变型异柠檬酸脱氢酶抑制剂的吡啶-2(1h)-酮喹啉酮衍生物
CN201580050441.5A CN107001328B (zh) 2014-09-19 2015-09-18 作为突变型异柠檬酸脱氢酶抑制剂的吡啶-2(1h)-酮喹啉酮衍生物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580050441.5A Division CN107001328B (zh) 2014-09-19 2015-09-18 作为突变型异柠檬酸脱氢酶抑制剂的吡啶-2(1h)-酮喹啉酮衍生物

Publications (2)

Publication Number Publication Date
CN111909130A CN111909130A (zh) 2020-11-10
CN111909130B true CN111909130B (zh) 2023-10-31

Family

ID=54291606

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202010391529.6A Active CN111909130B (zh) 2014-09-19 2015-09-18 作为突变型异柠檬酸脱氢酶抑制剂的吡啶-2(1h)-酮喹啉酮衍生物
CN201580050441.5A Active CN107001328B (zh) 2014-09-19 2015-09-18 作为突变型异柠檬酸脱氢酶抑制剂的吡啶-2(1h)-酮喹啉酮衍生物
CN202311265288.0A Pending CN117695280A (zh) 2014-09-19 2015-09-18 作为突变型异柠檬酸脱氢酶抑制剂的吡啶-2(1h)-酮喹啉酮衍生物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201580050441.5A Active CN107001328B (zh) 2014-09-19 2015-09-18 作为突变型异柠檬酸脱氢酶抑制剂的吡啶-2(1h)-酮喹啉酮衍生物
CN202311265288.0A Pending CN117695280A (zh) 2014-09-19 2015-09-18 作为突变型异柠檬酸脱氢酶抑制剂的吡啶-2(1h)-酮喹啉酮衍生物

Country Status (37)

Country Link
US (8) US9834539B2 (enExample)
EP (4) EP3194376B1 (enExample)
JP (1) JP6648115B2 (enExample)
KR (1) KR102209667B1 (enExample)
CN (3) CN111909130B (enExample)
AU (3) AU2015317329B2 (enExample)
BR (1) BR112017005238B1 (enExample)
CA (1) CA2961817C (enExample)
CL (1) CL2017000658A1 (enExample)
CO (1) CO2017003241A2 (enExample)
CY (2) CY1121149T1 (enExample)
DK (2) DK3447050T3 (enExample)
EA (1) EA034336B1 (enExample)
EC (1) ECSP17022933A (enExample)
ES (3) ES2790640T3 (enExample)
FI (1) FI3733662T3 (enExample)
HR (1) HRP20200666T1 (enExample)
HU (2) HUE062424T2 (enExample)
IL (3) IL292608B2 (enExample)
LT (2) LT3447050T (enExample)
MA (2) MA40481A (enExample)
ME (1) ME03776B (enExample)
MX (2) MX2017003404A (enExample)
MY (2) MY197533A (enExample)
NZ (1) NZ730373A (enExample)
PE (1) PE20171056A1 (enExample)
PH (1) PH12017500517B1 (enExample)
PL (3) PL3194376T3 (enExample)
PT (3) PT3194376T (enExample)
RS (2) RS58184B1 (enExample)
SA (1) SA517381129B1 (enExample)
SG (1) SG11201702194SA (enExample)
SI (2) SI3194376T1 (enExample)
SM (2) SMT201900018T1 (enExample)
TW (1) TWI686390B (enExample)
WO (1) WO2016044789A1 (enExample)
ZA (3) ZA201702127B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2755394C (en) 2009-03-13 2021-10-19 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
EP3064595B1 (en) 2009-10-21 2019-02-27 Agios Pharmaceuticals, Inc. Methods for cell-proliferation-related disorders
RU2685230C2 (ru) 2014-02-06 2019-04-17 Хептарес Терапьютикс Лимитед Бициклические азотсодержащие соединения как агонисты М1 мускариновых рецепторов
AU2015317322B2 (en) 2014-09-19 2020-09-17 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US9815817B2 (en) 2014-09-19 2017-11-14 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
JP6751081B2 (ja) 2014-09-19 2020-09-02 フォーマ セラピューティクス,インコーポレイテッド 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジニルキノリノン誘導体
PT3194376T (pt) 2014-09-19 2019-02-04 Forma Therapeutics Inc Derivados da piridin-2(1h)-ona-quinolinona como inibidores da isocitrato-desidrogenase mutante
WO2016042084A1 (en) 2014-09-19 2016-03-24 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 inhibitors
US10703746B2 (en) 2014-12-22 2020-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mutant IDH1 inhibitors useful for treating cancer
US10294206B2 (en) 2015-04-21 2019-05-21 Forma Tm2, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2016171756A1 (en) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
BR112019023152B1 (pt) 2017-05-04 2023-10-03 Discovery Purchaser Corporation Compostos heterocíclicos derivados de 2-{[2-(feniloximetil) piridina-5-il] oxi}-etanamina, seus usos e seus intermediários, formulações, e método para controle de pragas
WO2020232381A1 (en) 2019-05-16 2020-11-19 Forma Therapeutics, Inc. INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
PT3720442T (pt) * 2018-05-16 2023-03-13 Forma Therapeutics Inc Inibição de idh-1 mutante
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
EP4215197A1 (en) 2018-05-16 2023-07-26 Forma Therapeutics, Inc. Inhibiting mutant idh-1
TW202104207A (zh) * 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
US11566013B1 (en) * 2019-11-20 2023-01-31 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH1)
CN112341389B (zh) * 2020-10-27 2022-07-29 浙江工业大学 一种含氮芳杂环取代的喹啉甲酰胺类衍生物及其应用
CN112321571B (zh) * 2020-10-27 2022-06-03 浙江工业大学 2-呋喃-喹啉-4-甲酰胺类化合物及其应用
CN115850240B (zh) * 2022-12-28 2023-09-19 北京康立生医药技术开发有限公司 一种治疗急性髓系白血病药物奥卢他西尼的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011072174A1 (en) * 2009-12-09 2011-06-16 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
WO2013102431A1 (en) * 2012-01-06 2013-07-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2014141153A1 (en) * 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99731A0 (en) 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US20030105124A1 (en) 2000-04-27 2003-06-05 Susan Beth Sobolov-Jaynes Substituted benzolactam compounds
CA2488635C (en) 2002-06-12 2012-10-23 Abbott Laboratories Antagonists of melanin concentrating hormone receptor
AU2003284399A1 (en) 2002-11-14 2004-06-03 Kyowa Hakko Kogyo Co., Ltd. Plk inhibitors
RU2284325C2 (ru) * 2003-12-17 2006-09-27 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
JPWO2005095382A1 (ja) 2004-03-30 2007-08-16 協和醗酵工業株式会社 抗腫瘍剤
WO2006054912A1 (fr) 2004-11-18 2006-05-26 Obchestvo S Ogranichennoy Otvetstvennost'u 'asineks Medhim' Derives d'aryl(hetaryl)-3-aminomethylchinolone-2 utilises en tant qu'inhibiteurs de no-synthetase et de cyclo-oxygenase-2, procedes de leur fabrication et compositions pharmaceutiques sur leur base
TW200803855A (en) 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
JP2009543867A (ja) * 2006-07-17 2009-12-10 メルク エンド カムパニー インコーポレーテッド 抗hiv剤としての1−ヒドロキシナフチリジン化合物
JP2010043004A (ja) 2006-12-06 2010-02-25 Dainippon Sumitomo Pharma Co Ltd 新規2環性複素環化合物
ES2415163T3 (es) 2007-04-30 2013-07-24 Prometic Biosciences Inc. Derivados de triazina, composiciones que contienen tales derivados, y métodos de tratamiento de cáncer y enfermedades autoinmunitarias usando tales derivados
EP2440050A4 (en) 2009-06-08 2013-04-03 California Capital Equity Llc TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATION
WO2012006104A2 (en) 2010-06-28 2012-01-12 Academia Sinica, Taiwan Compounds and methods for treating tuberculosis infection
CN102558049B (zh) * 2010-12-17 2015-02-04 中国科学院上海药物研究所 一类双香豆素类化合物及其制备方法和用途
US20120184548A1 (en) 2011-01-19 2012-07-19 Romyr Dominique Carboxylic acid aryl amides
US20120184562A1 (en) 2011-01-19 2012-07-19 Kin-Chun Luk 1,6- and 1,8-naphthyridines
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN103814020B (zh) * 2011-06-17 2017-07-14 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
TWI547493B (zh) 2011-09-27 2016-09-01 諾華公司 作為突變idh之抑制劑之3-嘧啶-4-基-唑啶-2-酮
US9353121B2 (en) 2011-12-21 2016-05-31 The Regents Of The University Of Colorado, A Body Corporate Anti-cancer compounds targeting Ral GTPases and methods of using the same
WO2015003146A1 (en) 2013-07-03 2015-01-08 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
AU2015217788B2 (en) 2014-02-11 2019-06-27 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Benzimidazol-2-amines as mIDH1 inhibitors
US9815817B2 (en) 2014-09-19 2017-11-14 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
JP6751081B2 (ja) 2014-09-19 2020-09-02 フォーマ セラピューティクス,インコーポレイテッド 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジニルキノリノン誘導体
AU2015317322B2 (en) 2014-09-19 2020-09-17 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
PT3194376T (pt) 2014-09-19 2019-02-04 Forma Therapeutics Inc Derivados da piridin-2(1h)-ona-quinolinona como inibidores da isocitrato-desidrogenase mutante
US10703746B2 (en) 2014-12-22 2020-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mutant IDH1 inhibitors useful for treating cancer
GB2533925A (en) 2014-12-31 2016-07-13 Univ Bath Antimicrobial compounds, compositions and methods
WO2016171756A1 (en) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
US10294206B2 (en) 2015-04-21 2019-05-21 Forma Tm2, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US10253041B2 (en) 2015-07-27 2019-04-09 Eli Lilly And Company 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors
US20190046512A1 (en) 2016-02-26 2019-02-14 Agios Pharmaceuticals, Inc. Idh1 inhibitors for the treatment of haematological malgnancies and solid tumors
EP3464281B1 (en) 2016-06-06 2020-07-08 Eli Lilly and Company Mutant idh1 inhibitors
JP6987798B2 (ja) 2016-06-22 2022-01-05 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 癌の治療に変異体idh1阻害剤として有用なチアゾール誘導体
CA3045303C (en) 2016-12-16 2022-05-17 Eli Lilly And Company 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011072174A1 (en) * 2009-12-09 2011-06-16 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
WO2013102431A1 (en) * 2012-01-06 2013-07-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2014141153A1 (en) * 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh

Also Published As

Publication number Publication date
FI3733662T3 (fi) 2023-08-09
PH12017500517A1 (en) 2017-08-07
PL3194376T3 (pl) 2019-05-31
US9834539B2 (en) 2017-12-05
MX2017003404A (es) 2017-07-28
US20160083366A1 (en) 2016-03-24
ZA201902446B (en) 2023-12-20
SMT202000212T1 (it) 2020-05-08
KR20170063742A (ko) 2017-06-08
ES2953347T3 (es) 2023-11-10
MY176250A (en) 2020-07-24
CN107001328B (zh) 2020-06-05
CN111909130A (zh) 2020-11-10
EP3733662B1 (en) 2023-06-07
EA201790657A1 (ru) 2017-08-31
LT3447050T (lt) 2020-05-11
HRP20200666T1 (hr) 2020-07-24
KR102209667B1 (ko) 2021-01-29
US20170174658A1 (en) 2017-06-22
MA53352A (fr) 2021-09-15
WO2016044789A1 (en) 2016-03-24
MA40481A (fr) 2017-07-26
PL3733662T3 (pl) 2024-01-22
PL3447050T3 (pl) 2020-07-27
EA201790657A8 (ru) 2018-02-28
CO2017003241A2 (es) 2017-09-20
EP4257131A3 (en) 2024-01-10
IL282363A (en) 2021-06-30
AU2019283765A1 (en) 2020-01-16
AU2021215141B2 (en) 2023-10-19
SI3194376T1 (sl) 2019-03-29
ME03776B (me) 2021-04-20
US20240150319A1 (en) 2024-05-09
US20180312487A1 (en) 2018-11-01
MY197533A (en) 2023-06-21
LT3194376T (lt) 2019-02-25
AU2015317329A1 (en) 2017-04-27
US10550098B2 (en) 2020-02-04
EP3194376B1 (en) 2018-10-24
RS58184B1 (sr) 2019-03-29
IL292608B1 (en) 2024-06-01
DK3447050T3 (da) 2020-03-09
NZ758641A (en) 2023-12-22
EP3447050B1 (en) 2020-02-19
AU2021215141A1 (en) 2021-09-02
HUE041460T2 (hu) 2019-05-28
TWI686390B (zh) 2020-03-01
JP2017528487A (ja) 2017-09-28
ZA202304409B (en) 2024-08-28
MX385512B (es) 2025-03-18
EA034336B1 (ru) 2020-01-29
MX2019013203A (es) 2020-01-20
PT3447050T (pt) 2020-09-17
BR112017005238B1 (pt) 2023-01-17
EP3194376A1 (en) 2017-07-26
PT3194376T (pt) 2019-02-04
ES2704897T3 (es) 2019-03-20
SMT201900018T1 (it) 2019-02-28
EP3447050A1 (en) 2019-02-27
NZ730373A (en) 2019-11-29
ES2790640T3 (es) 2020-10-28
JP6648115B2 (ja) 2020-02-14
US20190263778A1 (en) 2019-08-29
IL251163B (en) 2021-05-31
CN117695280A (zh) 2024-03-15
HUE062424T2 (hu) 2023-11-28
US20230125739A1 (en) 2023-04-27
US12275715B2 (en) 2025-04-15
ZA201702127B (en) 2019-06-26
IL282363B (en) 2022-06-01
IL292608B2 (en) 2024-10-01
RS60140B1 (sr) 2020-05-29
SG11201702194SA (en) 2017-04-27
AU2019283765B2 (en) 2021-05-13
ECSP17022933A (es) 2017-08-31
TW201617335A (zh) 2016-05-16
CN107001328A (zh) 2017-08-01
PT3733662T (pt) 2023-08-18
BR112017005238A2 (pt) 2017-12-19
SA517381129B1 (ar) 2021-04-26
PE20171056A1 (es) 2017-07-21
CL2017000658A1 (es) 2017-12-22
CA2961817A1 (en) 2016-03-24
CA2961817C (en) 2024-03-12
CY1121149T1 (el) 2020-05-29
AU2015317329B2 (en) 2019-10-31
DK3194376T3 (en) 2019-01-21
CY1122865T1 (el) 2021-05-05
EP3733662A1 (en) 2020-11-04
US11498913B2 (en) 2022-11-15
IL292608A (en) 2022-07-01
US20200223822A1 (en) 2020-07-16
US20210078973A1 (en) 2021-03-18
SI3447050T1 (sl) 2020-08-31
EP4257131A2 (en) 2023-10-11
US10889567B2 (en) 2021-01-12
US10414752B2 (en) 2019-09-17
PH12017500517B1 (en) 2022-08-03
IL251163A0 (en) 2017-04-30

Similar Documents

Publication Publication Date Title
CN111909130B (zh) 作为突变型异柠檬酸脱氢酶抑制剂的吡啶-2(1h)-酮喹啉酮衍生物
JP6751081B2 (ja) 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジニルキノリノン誘導体
JP6820836B2 (ja) 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのフェニルキノリノン誘導体
HK40102356A (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HK40033589A (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HK40033589B (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HK40002980B (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HK40002980A (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HK1241376A1 (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HK1241376B (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant